Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for neuroprotection in stroke

CNS Neuroscience and Therapeutics

Volumn 19, Issue 10, 2013, Pages 773-784

  Peng, Tao ^a   Britton, George L ^a   Kim, Hyunggun ^a   Cattano, Davide ^a   Aronowski, Jaroslaw ^a   Grotta, James ^a   Mcpherson, David D ^a   Huang, Shao Ling ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cerebral ischemia; Liposomes; Neuroprotection; Stroke; Xenon

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG; XENON; XENON CONTAINING ECHOGENIC LIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INFARCTION SIZE; CELL DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE RESPONSE; ENZYME ACTIVATION; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THERAPEUTIC TIME WINDOW; THERAPY EFFECT;

CEREBRAL ISCHEMIA; LIPOSOMES; NEUROPROTECTION; STROKE; XENON;

ANIMALS; CELL DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; LIPOSOMES; MALE; NEUROPROTECTIVE AGENTS; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STROKE; TIME FACTORS; XENON;

EID: 84884815893     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/cns.12159     Document Type: Article

References (41)

1. Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States: Historical perspective and challenges ahead. Stroke 2011;42:2351-2355.
2. Suwanwela N, Koroshetz WJ. Acute ischemic stroke: Overview of recent therapeutic developments. Annu Rev Med 2007;58:89-106.
3. Kaufmann AM, Firlik AD, Fukui MB, Wechsler LR, Jungries CA, Yonas H. Ischemic core and penumbra in human stroke. Stroke 1999;30:93-99.
4. Fan X, Kavelaars A, Heijnen CJ, Groenendaal F, van Bel F. Pharmacological neuroprotection after perinatal hypoxic-ischemic brain injury. Curr Neuropharmacol 2010;8:324-334.
5. Fisher M. New approaches to neuroprotective drug development. Stroke 2011;42:S24-S27.
6. Irani Y, Pype JL, Martin AR, et al. Noble gas (argon and xenon)-saturated cold storage solutions reduce ischemia-reperfusion injury in a rat model of renal transplantation. Nephron Extra 2011;1:272-282.
7. Nakao A, Sugimoto R, Billiar TR, McCurry KR. Therapeutic antioxidant medical gas. J Clin Biochem Nutr 2009;44:1-13.
8. Qipshidze N, Metreveli N, Mishra PK, Lominadze D, Tyagi SC. Hydrogen sulfide mitigates cardiac remodeling during myocardial infarction via improvement of angiogenesis. Int J Biol Sci 2012;8:430-441.
9. Banks P, Franks NP, Dickinson R. Competitive inhibition at the glycine site of the N-methyl-D-aspartate receptor mediates xenon neuroprotection against hypoxia-ischemia. Anesthesiology 2010;112:614-622.
10. Dickinson R, Franks NP. Bench-to-bedside review: Molecular pharmacology and clinical use of inert gases in anesthesia and neuroprotection. Crit Care 2010;14:229.
11. Dworschak M. Pharmacologic neuroprotection-is xenon the light at the end of the tunnel? Crit Care Med 2008;36:2477-2479.
12. Sanders RD, Maze M. Xenon: From stranger to guardian. Curr Opin Anaesthesiol 2005;18:405-411.
13. Buchanan KD, Huang S, Kim H, Macdonald RC, McPherson DD. Echogenic liposome compositions for increased retention of ultrasound reflectivity at physiologic temperature. J Pharm Sci 2008;97:2242-2249.
14. Coussios CC, Holland CK, Jakubowska L, et al. In vitro characterization of liposomes and Optison by acoustic scattering at 3.5 MHz. Ultrasound Med Biol 2004;30:181-190.
15. Hamilton A, Rabbat M, Jain P, et al. A physiologic flow chamber model to define intravascular ultrasound enhancement of fibrin using echogenic liposomes. Invest Radiol 2002;37:215-221.
16. Huang S, Hamilton AJ, Tiukinhoy SD, et al. Liposomes as ultrasound imaging contrast agents and as ultrasound-sensitive drug delivery agents. Cell Mol Biol Lett 2002;7:233-235.
17. Huang SL, Hamilton AJ, Nagaraj A, et al. Improving ultrasound reflectivity and stability of echogenic liposomal dispersions for use as targeted ultrasound contrast agents. J Pharm Sci 2001;90:1917-1926.
18. Smith DA, Porter TM, Martinez J, et al. Destruction thresholds of echogenic liposomes with clinical diagnostic ultrasound. Ultrasound Med Biol 2007;33:797-809.
19. Britton GL, Kim H, Kee PH, et al. In vivo therapeutic gas delivery for neuroprotection with echogenic liposomes. Circulation 2010;122:1578-1587.
20. Maze LM, Bakas T. Factors associated with hospital arrival time for stroke patients. J Neurosci Nurs 2004;36:136-141, 55.
21. Guo S, Som AT, Waeber C, Lo EH. Vascular neuroprotection via TrkB- and Akt-dependent cell survival signaling. J Neurochem 2012;123(Suppl 2):58-64.
22. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. Trends Neurosci 1999;22:391-397.
23. Stankowski JN, Gupta R. Therapeutic targets for neuroprotection in acute ischemic stroke: Lost in translation? Antioxid Redox Signal 2011;14:1841-1851.
24. Broughton BR, Reutens DC, Sobey CG. Apoptotic mechanisms after cerebral ischemia. Stroke 2009;40:e331-e339.
25. Hsu CY, Ahmed SH, Lees KR. The therapeutic time window-theoretical and practical considerations. J Stroke Cerebrovasc Dis 2000;9:24-31.
26. Gappoeva MU, Izykenova GA, Granstrem OK, Dambinova SA. Expression of NMDA neuroreceptors in experimental ischemia. Biochemistry (Mosc) 2003;68:696-702.
27. Mio Y, Shim YH, Richards E, Bosnjak ZJ, Pagel PS, Bienengraeber M. Xenon preconditioning: The role of prosurvival signaling, mitochondrial permeability transition and bioenergetics in rats. Anesth Analg 2009;108:858-866.
28. Ma D, Lim T, Xu J, et al. Xenon preconditioning protects against renal ischemic-reperfusion injury via HIF-1alpha activation. J Am Soc Nephrol 2009;20:713-720.
29. Valleggi S, Cavazzana AO, Bernardi R, et al. Xenon up-regulates several genes that are not up-regulated by nitrous oxide. J Neurosurg Anesthesiol 2008;20:226-232.
30. Mattson MP, Duan W, Chan SL, et al. Neuroprotective and neurorestorative signal transduction mechanisms in brain aging: Modification by genes, diet and behavior. Neurobiol Aging 2002;23:695-705.
31. Zhang Y, Pardridge WM. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 2001;32:1378-1384.
32. Ma D, Hossain M, Pettet GK, et al. Xenon preconditioning reduces brain damage from neonatal asphyxia in rats. J Cereb Blood Flow Metab 2006;26:199-208.
33. Hetman M, Kanning K, Cavanaugh JE, Xia Z. Neuroprotection by brain-derived neurotrophic factor is mediated by extracellular signal-regulated kinase and phosphatidylinositol 3-kinase. J Biol Chem 1999;274:22569-22580.
34. Marushige K, Marushige Y. Changes in the mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling associated with the induction of apoptosis. Anticancer Res 1999;19:3865-3871.
35. Guo S, Kim WJ, Lok J, et al. Neuroprotection via matrix-trophic coupling between cerebral endothelial cells and neurons. Proc Natl Acad Sci U S A 2008;105:7582-7587.
36. Liu W, Liu Y, Chen H, Liu K, Tao H, Sun X. Xenon preconditioning: Molecular mechanisms and biological effects. Med Gas Res 2013;3:3.
37. Barreto G, White RE, Ouyang Y, Xu L, Giffard RG. Astrocytes: Targets for neuroprotection in stroke. Cent Nerv Syst Agents Med Chem 2011;11:164-173.
38. Almeida A, Delgado-Esteban M, Bolanos JP, Medina JM. Oxygen and glucose deprivation induces mitochondrial dysfunction and oxidative stress in neurones but not in astrocytes in primary culture. J Neurochem 2002;81:207-217.
39. Giffard RG, Swanson RA. Ischemia-induced programmed cell death in astrocytes. Glia 2005;50:299-306.
40. Chen Y, Swanson RA. Astrocytes and brain injury. J Cereb Blood Flow Metab 2003;23:137-149.
41. Li Y, Chopp M, Zhang ZG, Zhang RL. Expression of glial fibrillary acidic protein in areas of focal cerebral ischemia accompanies neuronal expression of 72-kDa heat shock protein. J Neurol Sci 1995;128:134-142.